Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or
statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) …

Significant advances in the management of cardiovascular disease have been made
possible by the development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) …

Abstract Treatment with the 3-hydroxy-3-methylglutaryl coenyzme A reductase inhibitors (or
statins) reduces the risk for cardiovascular events across a broad spectrum of patient …

Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of
hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels …

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent
inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the …

The discovery of statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) is a
consequence of the highly targeted, arduous search for naturally occurring compounds that …

The introduction of the hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) in 1987 was a major advance in the prevention and treatment of cardiovascular …

Background Statins are the most effective agents currently available for lowering plasma
levels of low-density lipoprotein cholesterol (LDL-C) and are the mainstay of therapy for …

Hyperlipidemia is recognized as one of the major risk factors for the development of
coronary artery disease and progression of atherosclerotic lesions. Dietary therapy together …

Cholesterol lowering involving different therapies improves the clinical outcome of patients.
To define the underlying pathomechanism, we studied whether treatment with statins was …